Gan & Lee Pharmaceuticals.
603087
Rankning i aktier
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aktiekurs
$10.03
Marknadsvärde
$5.99B
Förändring (1 dag)
-3.71%
Förändring (1 år)
2.30%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)
Kategori
Healthcare
Historik för aktiesplit för Gan & Lee Pharmaceuticals. (603087)
Aktien Gan & Lee Pharmaceuticals. (symbol: 603087) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 22, 2026.
En 603087-aktie köpt före Oct 22, 2026 motsvarar nu 0 603087-aktier.
Den senaste spliten skedde den Oct 22, 2026.
En 603087-aktie köpt före Oct 22, 2026 motsvarar nu 0 603087-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 3 | x4 |
US
|
|
| 3 | x20 |
FR
|
|
| 0 | - |
JP
|
|
| 6 | x20 |
US
|
|
| 0 | - |
CH
|
